Cellerant Therapeutics raises $4.4M for stem-cell therapeutics

April 26, 2007 | Matt Marshall

Cellerant Therapeutics, a San Carlos, Calif. developer of stem cell therapeutics for things like sickle cell disease treatment, has raised $4.4 million in a second round financing. It was reported by VentureWire (sub required), which cited a Securities and Exchange Commission filing.

Cellerant previously raised $25 million towards its Series B funding, having last added $9 million to the round in September 2005. Before that, the company also raised a $10 million funding in May 2003. Cellerant’s investors include Camelot Ventures, Eminent Venture Capital Group, Amgen Founder George Rathmann, Novel Bioventures, CX Venture Group, MPM Capital, Allen & Co. and BD Ventures.

Next Story: MySpace, armed with as much as $100M, goes to China
Previous Story: Motorola backs Vocera, maker of wearable badge for wireless communication

Twitter

Facebook

Google Buzz

Digg

StumbleUpon

Delicious

Google

More...

About the Author, Matt Marshall

Matt launched VentureBeat in September of 2006, with the realization that no one else was covering the entrepreneurial and tech innovation scene with the velocity or depth that he was. Prior to founding VentureBeat, he covered venture capital for the San Jose Mercury News from 2001 to 2006. In 2002, Matt was awarded "Journalist of the Year" by the Northern California Society of Professional Journalists. Prior to working at the Merc, he was a correspondent for the Wall Street Journal in Bonn, Germany from 1995 to 1998, and a writer for the Washington Post in 1994. Matt holds a PhD in Government and an MA in German and European Studies from Georgetown University. In addition to VentureBeat, Matt is also the Executive Producer of DEMO, the leading launchpad event for emerging technologies.